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Introduction
More than ever in history, vaccines in this Carcinoma vary to some extent in different 
century promise to be the first and best line regions of the world. In all regions, types 16 
of defence against disease. With the and 18 are the most common, together 
availability of human papilloma virus (HPV) accounting for 73.5% of cancers in Asia, 
vaccine, primary prevention of both about 65% in Africa and central/south 
America, and 71.5% in Europe and the 
Precancerous and cancerous cervical lesion United States. The next most common 
1 genotypes include types 45 in Africa and is now possible . Together, screening and 
Asia; 31 in Latin America, 33 in Europe and vaccination will potentially further reduce 
2, 3the enormous burden of cervical cancer North America and 58 and 52 in Asia . In 
worldwide. Human papilloma virus is the many developing countries, awareness of 
most common viral infection of the the role of HPV in cervical cancer is low even 
reproductive tract worldwide often regarded among physicians and other health 
2, 4, 5as the common cold virus of the genital tract professionals .
2
and infects an estimated 660 million people . 
While HPV infection resolves spontaneously Worldwide, cancer of the cervix continues to 
in the majority of people, it can develop into be the second commonest female cancer 
chronic infection and, in some women, into and affects approximately 1.4 million 
cervical cancer. The peak incidence of HPV women with more than half a million new 
infection occurs in adolescents and young cases and half of these die as a result every 
women, while cervical cancer typically year. The highest incidence rates are 
follows 20–30 years later. The five most observed in sub-Saharan Africa and Latin 
2, 6common HPV types in squamous cell cervical America . The disease represents a major 
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Abstract
Background: In 2006, the world’s first cervical cancer vaccine became available for public use. 
Two human papilloma virus (HPV) vaccines, Gardasil & Cervarix were licensed, both protecting 
against the most common cancer-causing HPV types (HPV 16 and 18), and Cervarix also 
protecting against genital warts (including in addition, types 6 and 11). A good understanding of 
the vaccine, its role in the primary prevention of cervical cancer and pre cancers is vital in 
reducing the high morbidity and mortality associated with cervical cancer.
Objective: This article provides an overview of cervical cancer vaccine including safety, efficacy 
and cost in the primary prevention of cervical cancer.
Discussion: The quadrivalent human papilloma virus (HPV) vaccine protects against HPV types 
6, 11, 16 and 18. These HPV types are responsible for 70% of cervical cancers, 90% of genital 
warts and a substantial proportion of cervical abnormalities. The quadrivalent human 
papilloma virus (HPV) vaccine is indicated for females aged 9 -26 years and males aged 9-15 
years and should ideally be administered before the onset of sexual activity, however, sexually 
active patients will also benefit. These vaccines are expected to be able to prevent about 70% of 
cervical cancer cases worldwide
Keywords: Human Papilloma Virus, Vaccine, Immunization
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health inequity, as 90% of those with cervical Human Papilloma Virus (HPV) 
cancer live in developing countries. Though, Overview
Cervical cancer is a preventable disease yet Human papilloma virus is a common virus 
invasive cervical cancer remains the most that affects both males and females. HPV is 
common cancer in the developing countries now universally recognised as a necessary 
and the second leading cause of cancer agent for the development of cervical cancer 
mortality in women due to poor prognosis with HPV being present in 99.7% of cervical 
3attributed to lack of awareness about the cancers . The virus is also associated with 
disease and its prevention, late presentation o ve r  9 0 %  o f  g e n i ta l  wa r t  c as es ,  
i n  ad va n c ed  s t a ge  w h e n  c u re  i s  approximately 70% of anal cancers, 
unrealistically impossible with overburden approximately 50% of penile cancer lesions, 
of the limited and inadequate facilities, and approximately 20% of oropharyngeal 
3ineffective cervical cancer screening cancers . HPV16 and HPV18 account for 70% 
programme, dearth of women education of cervical cancers but infection only rarely 
2,7,8,9and empowerment . India recorded over leads to cancer (<2%) with a15 year lag 
2130 000 new cases of cervical cancer in 2002 period between infection and cancer . Up 
and accounted for approximately 25% of the until now, detection of precancerous cervical 
world’s burden of cervical cancer. The exact lesions was the key to preventing cervical 
burden of cervical cancer in Nigeria remain cancer through regular gynaecological 
unknown but of public health significance. screening programmes that allow early 
The high incidence of invasive cervical detection and treatment of precancerous 
cancer rates in Nigeria reflects an inactive lesions. In developing countries, however, 
national cervical Pap screening program. In this method has had only a limited impact 
Ilorin, Nigeria  62.3% of gynaecological due to the cost and complexity of properly 
cancers were histologically confirmed screening and treating women. In a study 
9
primary cervical cancers . The link between from a tertiary health institution in Nigeria, 
sex, human papilloma virus infection and only 5.2% of female health workers had had 
5cervical cancer has long been established. previous Pap smear . There are over 100 HPV 
Marriage, sexual activity, multiple sexual subtypes including 40 anogenital types with 
partners or cohorts, increase in parity are some 15 high risk (oncogenic) types such as 
epidemiological determinants of cervical HPV 16, 18, 31 and 45 conferring cervical 
cancer. cancer risks. High risk HPV types are found in 
Before the introduction of cervical screening different proportions throughout the world; 
programmes in the 1960s and 1970s, the however HPV 16 and 18 are responsible for 
incidence of cervical cancer in developed at least 70% of cervical cancers and 50% of 
1, 2, 6countries was similar to what obtain in high grade lesions worldwide . Low risk 
developing countries today. Incidence rates subtypes such as 6 and 11 are involved in 
are now low in developed countries, but this greater than 90% of genital warts and 
pattern is relatively recent. Industrialized approximately 10% of low grade cervical 
1,2countries have greatly reduced deaths from abnormalities   (Table 1)
cervical cancer through effective screening 
programmes that allows early detection and Natural History of Human Papilloma Virus 
treatment. These programmes are inactive, (HPV)
expensive and difficult to implement in low- Human papilloma virus is a non enveloped 
income countries. double stranded circular DNA virus. The virus 
is highly infective with transmission rates of 
over 50% following exposure to a person 
13 epithelial lesions (LSIL) seen on Pap smears with productive anogenital HPV infection . 
reflect acute infection with HPV and The highest prevalence of HPV infection has 
regression occurs in most cases. Much of the been identified in   sexually active women 25 
burden of this low grade disease occurs in years of age and younger. Up to 80% of 
young women. High grade squamous sexually active women and men will be 
intraepithelial lesions (HSIL) as noted on Pap exposed to at least one type of HPV in their 
smears probably represent viral persistence lifetime. Most people get their first type of 
and integration of HPV DNA and require HPV infection within their first few years of 
treatment. Progression of these lesions and becoming sexually active. While the 
the development of invasive squamous infection is so easily passed on, more than 
carcinoma of the cervix can occur over time. 90% of infections are cleared by the body 
In Nigeria, approximately 80% of these high immune system within the first two 
13 grades cervical abnormalities occur in years .Infection with the anogenital types 
w o m e n  u n d e r  t h e  a g e  o f  4 0  occurs largely through any type of genital 
14years Procedures to remove these lesions contact and not necessarily genital 
are associated with increased risk for penetrat ion.  Condoms can reduce 
15
transmission, but do not prevent infection. adverse pregnancy outcomes .
Condoms does not offer complete 
protection against HPV infection as it is Development of Human Papilloma (HPV) 
t ra n s m i tted  t h ro u g h  ge n i t a l  sk i n  Vaccine
3 Vaccination aims to produce neutralising contact ,Human Papilloma virus enters the 
antibodies capable of preventing infection body through micro abrasions in the 
by binding tightly to the surface of the virus anogenital skin and replicates in the basal 
and physically preventing the virus from epithelial cells. Infection is often subclinical 
docking with, and attaching to, a host cell. but may present as condyloma (warts), 
Human papilloma virus capsid structural cervical or anogenital abnormalities and 
proteins are the logical target for such cancers. Most women who contract HPV 
antibodies, but HPV itself has been infection clear it spontaneously within a 
notoriously difficult to artificially culture. median of 8–14 months with persistence of a 
The landmark discovery of the ‘late’ capsid high risk HPV type only occurring in 3–10% of 
proteins ‘L1’ is widely recognised as leading women. Persistent HPV infection is a key 
to the development of the HPV vaccine. biological  intermediate in cervical  
Australian research team at the University of carcinogenesis.  Low grade squamous 
Table 1. Effects of HPV Infection in Women & Men
HPV type Women                      Men
16/18 (High risk subtypes) •70% of cervical cancer2   • Most anal cancers2
• 50% of CIN 2/36 (HSIL)  
• 25% of CIN 17 (LSIL) • Potentially prevention of 
•Most anal cancers2 Infection (reduced Transmission
on to Women) 
6/11(Low risk Subtypes) • 10% of CIN 112 • Potentially prevention of 
• >90% of genital warts10  infection(reduced Transmission
 on to Women)
• >90% of genital warts10
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Queensland led by Professor Ian Frazer, and N at i o n a l  h u m a n  pa p i l l o m a  ( H P V )  
Dr Jian Zhou, identify the VLPs. L1 assembles vaccination program to females aged 12 to 
to form empty capsids, known as virus-like 26 years.
particles (VLPs) when expressed in yeast or 
other cells. VLPs contain no infectious Efficacy of Human Papilloma (HPV) Vaccine
genetic material and because they are Efficacy trials for the quadrivalent HPV 
recombinant proteins have no oncogenic or vaccine included two randomised, double 
disease causing potential, therefore being blind, placebo controlled trials – FUTURE I 
ideal for use as vaccines. The quadrivalent and II. In these studies 5746 and 12 157 
HPV vaccine contains highly purified VLPs of women aged 16 to 26 years respectively, 
1the major capsid protein (L1) of the HPV were evaluated in 33 countries.  The clinical 
types 6, 11, 16 and 18. The VLPs mimic the trials did not exclude women with evidence 
shell of the virus and are capable of of HPV infection. Of the approximately 20 
2
generating potent antibody responses . 000 mostly sexually active women enrolled 
The HPV vaccines are developed from DNA- in the phase II and III clinical trial program, 
free virus-like particles (VLPs) synthesized by 73% were naïve to all four vaccine HPV types 
1self-assembly of fusion proteins of the major before vaccination.
capsid antigen L1. Cervarix vaccine is a After a follow up of approximately 2 years 
quadrivalent vaccine containing L1 VLPs of (on average) among women who were naive 
types 6, 11, 16 and 18 expressed in S. to the relevant HPV types before vaccination, 
cerevisiae yeast. Inclusion of types 6 and 11 the efficacy of the quadrivalent HPV vaccine 
in a prophylactic vaccine is expected to was 100% for the prevention of HPV 16 or 18 
prevent more than 90% of cases of genital related cervical intraepithelial neoplasia 
warts and to protect against the early ( C I N )  g r a d e  2  o r  w o r s e  o r  A I S  
cervical dysplasia seen with types 6 and 11. (adenocarcinoma in situ), 95% efficacy for 
Gardasil vaccine contains VLPs of types 16 the prevention of CIN (any grade) caused by 
and 18 and is based on recombinant HPV 6, 11, 16 or 18 and 99% efficacy for the 
baculovirus technology. These vaccines are prevention of external genital lesions 
expected to be able to prevent about 70% of (genital warts and vulvar or vaginal 
cervical cancer cases worldwide, among intraepithelial lesions) due to the vaccine 
1,16women who have not yet been infected with HPV types.
HPV of high-risk types (to date, there are no Evidence of efficacy was observed to 
sufficient data regarding prevention of commence during the vaccination period.
cancer among women who have already The vaccine is best administered before the 
experienced an infection). The prevalence of onset of sexual activity and therefore before 
types 16 and 18 varies between countries, potential infection with HPV, however, 
however, and the coverage would be slightly sexually active women also stand to benefit 
lower (around 65%) in Latin America and from vaccination. In women with previous 
sub-Saharan Africa. A vaccine that included HPV infection, as indicated by the presence 
the seven most common HPV types of either antibodies or HPV DNA in samples 
worldwide (16, 18, 31, 33, 45, 52, 58) is at baseline, the vaccine was effective in 
predicted to be able to prevent 87% of all preventing disease due to the remaining HPV 
cases, with little regional variation.  As of the types (to which they were naïve). Among 
end of 2006, the vaccine had been approved women seropositive or DNA positive to one 
in 49 countries worldwide, with more or more of the vaccine HPV types, the 
2expected to join the list in later years .  From vaccine was 100% effective against CIN 2 or 
April 2007, Australian introduced free worse or AIS due to the remaining HPV types. 
The vaccine was also highly effective against the greatest benefit being derived if 
external genital lesions.14 Currently, efficacy administered before the onset of sexual 
data to 5 years is available from the phase II activity. Even if a patient has been sexually 
trials, where the combined incidence of HPV active and infected with one of the four types 
6,11, 16, and 18 related persistent infection in the quadrivalent HPV vaccine, they will 
or disease was reduced in vaccine recipients still benefit from vaccination against the 
15 other three. In clinical studies of the women by 96%.  The overall efficacy of quadrivalent 
who had been infected with at least one HPV vaccine  will depend on the baseline 
vaccine HPV type, most were infected with prevalence of HPV infection and disease in 
1 only one type1 Therefore sexually active the population vaccinated.  This is because 
women should not be discouraged or the quadrivalent HPV vaccine has not been 
excluded from vaccination.shown to protect against the consequences 
It is important to note, HPV vaccination is not of all HPV types and will not protect against 
a substitute for a Pap test and women should established disease caused by the HPV types 
be instructed to continue with regular contained in the vaccine.
screening as not all oncogenic or high risk 
types are covered by the current vaccine. In Immunogenicity
addition, vaccination is not a treatment for The quadrivalent HPV vaccine appears to be 
existing HPV related disease – it is preventive highly immunogenic. Over 99.5% of subjects 
of infection with four HPV types. Efficacy became seropositive to all four HPV types by 
studies are ongoing in men and older women one month after the third dose. Antibody 
with data likely to be available in 2–3 years.levels induced by the vaccine were 
substantially higher than those observed in 
Protocol for Vaccinationwomen with evidence of natural HPV 
The quadrivalent HPV vaccine is available as infection and a subsequent immune 
1 a pre filled syringe for ease of use. Each 0.5 response. Antibody levels in males aged 
ml dose contains approximately 225 µg of 10–15 years and females were significantly 
a luminium adjuvant.  I t  should be superior to that observed in those aged 
administered intramuscularly in three doses 16–23 years. Immunogenicity data has been 
of 0.5 ml, at 0, 2 and 6 months. It is generally used to link efficacy in females 16–26 years 
1 considered to be best administered at the to the younger populations.  Antibody 
age of nine to 13 years, before girls become response appears prolonged and evidence of 
sexually active and potentially exposed to an immune memory response has been 
17 HPV. However, in clinical studies efficacy has observed. Sentinel cohorts have been set 
been demonstrated in individuals who have up to evaluate long term efficacy well in 
received all three doses within 1 year. If an advance of the general population. The need 
alternative vaccination schedule is for booster vaccination is not yet 
necessary, the second dose should be established, although long term protection is 
administered at least 1 month after the first anticipated. Other similar models such as 
18 dose and the third dose should be hepatitis B vaccination, give confidence for 
administered at least 3 months after the long term protection.
1second dose.   Concomitant administration 
of quadrivalent HPV vaccine with hepatitis B Vaccination Target Group
vaccine has been demonstrated as safe and The quadrivalent HPV vaccine is registered 
as immunogenic as when injections are given for use in females 9–26 years of age and 
11 separately.  Partnership between health males aged 9–15 years.  Vaccination will 
programmes is vital for a coordinated benefit all patients within this age group with 
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introduction of the vaccine, and to deliver cost–effective way to reduce the incidence 
other interventions while immunizing of cervical cancer. However, cost is a major 
against HPV. It’s important to make sure that barrier to making the vaccine widely 
HPV vaccine is available globally especially available especially where it is most needed. 
for females at risk in developing countries Current price of approximately US$ 90 a dose 
through concerted efforts of national and for a three-dose vaccination schedule make 
international organizations. The vaccine is the vaccine expensive and unaffordable but 
also on the WHO prequalification list, which still far cheaper than the morbidity & 
could open the door to purchases in mortality cost of cancer of cervix even in the 
developing countries via United Nations poorest countries. It’s expected to become 
2 cheaper and widely available in the nearest agencies
future.
  Side Effects and Safety
Strategy for Cervical Cancer Vaccination in In clinical trials, quadrivalent HPV vaccine 
Nigeriademonstrated a favourable safety profile 
Cervical cancer is the leading cause of when compared with placebo. Few subjects 
morbidity and mortality of all malignancies (0.2%) discontinued due to adverse 
in Nigerian women. Collaborative and experiences. Local symptoms such as 
concerted efforts by government, women injection site reactions (pain, swelling, and 
and professional organisations and erythema) were reported. The majority of 
individuals will be needed to combat a patients (94.4%) who received the vaccine 
potentially preventable sexually transmitted judged their injection site reaction to be mild 
cancer. A well focused political will by or moderate in intensity. Fever has also been 
1 government is central to a cervical cancer reported.  Approx imate ly,  10% of  
vaccination as part of a comprehensive participants in the FUTURE studies became 
reproductive health package. Professional pregnant and were instructed to defer 
organisations such as SOGON would be completion of the vaccination regimen until 
required to work with bodies with similar resolution of the pregnancy. Outcomes of 
interest in the areas of research, policy these pregnancies were comparable in 
formulat ion  & implementat ion  of  subjects who received placebo and subjects 
reproductive health issues and formulating a who received the quadrivalent HPV vaccine. 
sexual health education package for However, women should not electively 
adoption in all schools. Nigeria needs to vaccinate if pregnant. The quadrivalent HPV 
introduce a school vaccination programme vaccine  has been designated Category 
targeted at girls at entry to secondary school B2status in pregnancy. There is no 
for simultaneous administration of HPV contraindication to the use of the vaccine 
vaccine with tetanus toxoid, measles, during lactation.1 Normal precautions such 
mumps and rubella vaccines. The vaccine as not vaccinating during a moderate to 
should be funded for females aged 12–26 severe febrile illness and inquiry into 
years. The National Immunisation Program hypersensitivity to yeast or other vaccine 
should  be  repackaged to  achieve  component(s) should be followed.1
immunisation of Nigerian children where 
they live to reduce the overall disease Cost Implications
burden. While support of international Globally, the primary aim of HPV vaccination 
agencies would still be needed to make the will be to prevent cervical cancer. Human 
vaccine affordable and available, it will papilloma virus (HPV) vaccines have the 
remain an illusion to continue to depend on potential to be a more practical and 
donor agencies to improve the health status 
of Nigerians. Screening and treatment Summary of Important Points
services for cervical cancer will still be • The quadrivalent HPV vaccine protects 
required as the vaccines only prevents about against HPV types 6, 11, 16 and 18.
70% of cervical cancer cases and it would be • HPV types 16 and 18 cause 70% of cervical 
years, if not decades, before the full benefit cancer cases and 50% of high grade cervical 
of vaccination in terms of a reduction in the abnormalities.
incidence of cervical cancer occurs. Female • HPV types 6 and 11 cause 90% of cases of 
education and women empowerment genital warts and approximately 10% of low 
remain core and pertinent to enhance grade cervical abnormalities.
reproductive health in Nigeria. • Vaccination is indicated for females aged 
9–26 and males aged 9–15 years.
Conclusion • Best time to vaccinate: the sooner the 
Human papilloma virus vaccination presents better – ideally before onset of sexual 
a paradigm shift in the management of activity, although sexually active women will 
cervical cancer. Combined with cervical also benefit.
screening, vaccination will provide women • Women should continue with regular Pap 
with their best chance of protection against tests as not all oncogenic or high risk types 
cervical cancer and cervical abnormalities. are covered by the vaccine.
The quadrivalent HPV vaccine is indicated for • Vaccination is not a treatment for existing 
females aged 9–26 years and males aged HPV related disease – it is preventive of 
9–15 years and should ideal ly be infection with four HPV types.
administered before the onset of sexual 
activity, however sexually active individuals 
will also benefit. 
References
1. Gardasil Product Information TGA Approved 5. Udigwe GO: Knowledge, attitude and 
June 2006. Available at practice of cervical cancer screening (pap 
www.cervicalcancer.com.au/healthprofres smear) among female nurses in Nnewi, 
ources.asp [Accessed 31 March 2007]. South Eastern Nigeria. Nigerian Journal of 
2. World Health Organisation. April 2005. Clinical Practice Vol. 9(1) 2006
Report of the Consultation on Human 6. Shafi MI: Premalignant and malignant 
Papillomavirus vaccines. Available at disease of the cervix In: Keith Edmonds(ed), 
www.who.int/vaccinesdocuments/ Dewhurst’s Textbook of Obstetrics and 
DocsPDF05/816screen.pdf Gynaecology for Postgraduates, 6th edition, 
[Accessed 29 March 2007]. Blackwell Scientific pub. Pp 572-581.
3. Walboomers JMV, Manos MM, et al. Human 7. Ijaiya MA, Aboyeji PA, BuhariMO: Cancer of 
papillomavirus is a necessary cause of the cervix in Ilorin,Nigeria. West African 
invasive cervical cancer worldwide. J Pathol Journal of Medicine Vol.23(4) 2004: 319-322
1999;189:12–9. 8. Airede LR ,Malami SA: A five-year review of 
4. Peter O. Adefuye, Olabisi Onabanjo female genital tract malignancies in Sokoto, 
University Teaching Hospital, Sagamu, Ogun Northwestern Nigeria. Mary Slessor Journal
State, Nigeria Knowledge and practice of of Medicine Vol. 5(1), 2005: 51-56
cervical cancer screening among female 9. Ijaiya MA, Aboyeji AP, Olatinwo AWO, Buhari 
professional health workers in a sub-urban MO: Clinico-pathological presentation of 
district of Nigeria Nigerian Medical primary cervical cancer seen in Ilorin, 
Practitioner Vol. 50(1) 2006: 19-22 Nigeria. Nig. J. of Surgical Research Vol.4(3-
8
Trop J Obstet Gynaecol, 25 (1), April 2008.                                                                                               ISSN 0189 5178
4) 2002: 89-93 treatment for intraepithelial or early invasive 
10. Clifford GM, Rana RK, Franceschi S, et al. cervical lesions: systematic review and 
H u m a n  p a p i l l o m a v i r u s  g e n o t y p e meta-analysis. Lancet 2006;367:489–98.
distribution in low grade cervical lesions: 13. Banatvala JE, Van Damme P. Hepatitis B 
comparison by geographic lesions and with vaccine: do we need boosters?
cerv ica l  cancer.  Cancer  Ep idemiol  J Viral Hepat 2003;10:1–6.
Biomarkers Prev 2005;14:1157–64. 14. Villa LL, Costa RLR, Petta CA, et al. Induction 
11. Jimoh AS, Abdul IF: A Review of One Hundred o f  i m m u n e  m e m o r y  f o l l o w i n g
and Three (103) Histologically Confirmed ad m i n i s t ra t i o n  o f  a  p ro p hy l a c t i c
Cases of Carcinoma of the Cervix at the quadrivalent human papillomavirus
University of Ilorin Teaching Hospital, Ilorin, (HPV) types 6/11/16/18 L1 virus-like particle 
Nigeria. Nigerian Medical Practitioner Vol. (VLP) vaccine.
45 No 4, 2004(56-60) [Abstract] International Society for 
12. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et Infectious Diseases. 2006 June 15–18; Lisbon
al. Obstetric outcomes after conservative 
